These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38304628)

  • 1. PRPF19 functions in DNA damage repair and gemcitabine sensitivity via regulating DDB1 in bladder cancer cells.
    Yu J; Ge S
    Cytotechnology; 2024 Feb; 76(1):85-96. PubMed ID: 38304628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PRPF19 promotes the proliferation, migration, and inhibits autophagy in prostate cancer by suppressing SLC40A1.
    Zhang G; Zhang W; Dan M; Zou F; Qiu C; Sun C
    Chin J Physiol; 2023; 66(5):379-387. PubMed ID: 37929350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Petite Integration Factor 1 knockdown enhances gemcitabine sensitivity in pancreatic cancer cells via increasing DNA damage.
    Wang K; Hua X; Fu X; Hao Z; Jiao A; Li S
    J Appl Toxicol; 2023 Oct; 43(10):1522-1532. PubMed ID: 37183367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Damage DNA-Binding Protein 1 in Pancreatic Cancer Progression and Chemoresistance.
    Zhang Y; Lei Y; Xu J; Hua J; Zhang B; Liu J; Liang C; Meng Q; Yu X; Shi S
    Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31842285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Integrated Analysis of the Identified PRPF19 as an Onco-immunological Biomarker Encompassing the Tumor Microenvironment, Disease Progression, and Prognoses in Hepatocellular Carcinoma.
    Yang M; Qiu Y; Yang Y; Wang W
    Front Cell Dev Biol; 2022; 10():840010. PubMed ID: 35252202
    [No Abstract]   [Full Text] [Related]  

  • 6. Up-regulation of
    Azhati B; Maolakuerban N; Ma T; Li X; Rexiati M
    Arch Med Sci; 2020; 16(5):1207-1217. PubMed ID: 32864010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PRPF19 promotes tongue cancer growth and chemoradiotherapy resistance.
    He Y; Huang C; Cai K; Liu P; Chen X; Xu YI; Ming Z; Liu Q; Xie Q; Xia X; Sun Y; Luo J; Wei R
    Acta Biochim Biophys Sin (Shanghai); 2021 Jul; 53(7):893-902. PubMed ID: 33954334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PTK6 Potentiates Gemcitabine-Induced Apoptosis by Prolonging S-phase and Enhancing DNA Damage in Pancreatic Cancer.
    Ono H; Basson MD; Ito H
    Mol Cancer Res; 2015 Aug; 13(8):1174-84. PubMed ID: 26013168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PRPF19 facilitates colorectal cancer liver metastasis through activation of the Src-YAP1 pathway via K63-linked ubiquitination of MYL9.
    Zhou R; Chen J; Xu Y; Ye Y; Zhong G; Chen T; Qiu L
    Cell Death Dis; 2023 Apr; 14(4):258. PubMed ID: 37031206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long noncoding RNA NORAD acts as a ceRNA mediates gemcitabine resistance in bladder cancer by sponging miR-155-5p to regulate WEE1 expression.
    Yang Y; Zhang G; Li J; Gong R; Wang Y; Qin Y; Ping Q; Hu L
    Pathol Res Pract; 2021 Dec; 228():153676. PubMed ID: 34753061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzalutamide inhibits proliferation of gemcitabine-resistant bladder cancer cells with increased androgen receptor expression.
    Kameyama K; Horie K; Mizutani K; Kato T; Fujita Y; Kawakami K; Kojima T; Miyazaki T; Deguchi T; Ito M
    Int J Oncol; 2017 Jan; 50(1):75-84. PubMed ID: 27909718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salinomycin suppresses T24 cells by regulating KDM1A and the unfolded protein response pathway.
    Yuan H; Li Y; Zou Y; Cai C; Shi X; Su Y
    Cytotechnology; 2022 Oct; 74(5):579-590. PubMed ID: 36238269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PRPF19 regulates p53-dependent cellular senescence by modulating alternative splicing of MDM4 mRNA.
    Yano K; Takahashi RU; Shiotani B; Abe J; Shidooka T; Sudo Y; Yamamoto Y; Kan S; Sakagami H; Tahara H
    J Biol Chem; 2021 Jul; 297(1):100882. PubMed ID: 34144037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Forkhead Box R2 Knockdown Decreases Chemoresistance to Cisplatin via MYC Pathway in Bladder Cancer.
    Li Y; Zu X; Hu X; Wang L; He W
    Med Sci Monit; 2019 Nov; 25():8928-8939. PubMed ID: 31761897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circular RNA CircHIPK3 Promotes Gemcitabine Sensitivity in Bladder Cancer.
    Xie F; Zhao N; Zhang H; Xie D
    J Cancer; 2020; 11(7):1907-1912. PubMed ID: 32194801
    [No Abstract]   [Full Text] [Related]  

  • 16. Long non-coding RNA GHET1 contributes to chemotherapeutic resistance to Gemcitabine in bladder cancer.
    Li B; Xie D; Zhang H
    Cancer Chemother Pharmacol; 2019 Jul; 84(1):187-194. PubMed ID: 31115606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Berberine enhances gemcitabine‑induced cytotoxicity in bladder cancer by downregulating Rad51 expression through inactivating the PI3K/Akt pathway.
    Gao X; Liu J; Fan D; Li X; Fang Z; Yan K; Fan Y
    Oncol Rep; 2022 Feb; 47(2):. PubMed ID: 34935059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of DDB1 is associated with subtypes of epithelial ovarian cancer and predicts clinical outcomes.
    Shan Y; Mao B; Jin Y; You Y; Wang Y; Shen K; Li L
    Tissue Cell; 2023 Jun; 82():102072. PubMed ID: 36934683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BMI1 activates P-glycoprotein via transcription repression of
    Chen MK; Zhou JH; Wang P; Ye YL; Liu Y; Zhou JW; Chen ZJ; Yang JK; Liao DY; Liang ZJ; Xie X; Zhou QZ; Xue KY; Guo WB; Xia M; Bao JM; Yang C; Duan HF; Wang HY; Huang ZP; Qin ZK; Liu CD
    Aging (Albany NY); 2021 Jul; 13(14):18310-18330. PubMed ID: 34270461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine impacts differentially on bladder and kidney cancer cells: distinct modulations in the expression patterns of apoptosis-related microRNAs and BCL2 family genes.
    Papadopoulos EI; Yousef GM; Scorilas A
    Tumour Biol; 2015 May; 36(5):3197-207. PubMed ID: 25833690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.